+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

EU (European Union) Pharmaceutical Regulations & Strategy Training Course (ONLINE EVENT: June 10-11, 2024)

2 Days: June 10th 09:00 - June 11th 17:00 GMT
  • Conference
  • Management Forum
  • ID: 5922643

Creating and coordinating an effective regulatory strategy is an essential part of the work of a regulatory affairs department and can save valuable time and money.

This interactive course will provide an overview of the European pharmaceutical regulatory environment, procedures and obligations and discuss how to interpret and apply the legislation. 

The programme will cover the legal basis of regulation, development strategies and the importance of pre-submission activities as well as an overview of the format for presentation of data, the registration procedures for obtaining marketing authorisations and post-authorisation obligations and strategic considerations. The impact of post-Brexit changes for obtaining and maintaining marketing authorisations in the UK will be considered.

There will be a number of case study sessions throughout the two days to explore options and strategies for these key regulatory activities, which will provide an opportunity for discussion and the sharing of experiences with our expert trainer and other delegates.

Benefits of attending

  • Understand the legal basis of the EU regulatory environment
  • Discuss development strategy and pre-submission activities
  • Review procedures for applying for a marketing authorisation in the EU/EEA and in the UK
  • Discuss post-authorisation strategic considerations and obligations
  • Explore the impact of post-Brexit changes
  • Discuss the proposed EU pharmaceutical legislation changes

Certification:

  • CPD: 12 hours for your records
  • Certificate of completion

Agenda

DAY 1

EU regulatory environment: legal basis

  • Key regulations, directives and guidelines
  • Impact of Brexit
  • Proposed EU pharmaceuticals legislation (specific changes will be discussed in the relevant section of the programme)

Information sources

Case Study One

Development and Strategy

  • Drug discovery
  • Scientific advice

Development process

  • Pharmaceutical R&D
  • Non-clinical tests
  • Clinical studies - Phase I to III

EU Clinical Trials Regulation

Types and categories of marketing Authorisations

Adaptive marketing authorisation procedures

The Common Technical Document (CTD)

  • Overview of Structure and content of a CTD

Procedures for obtaining a marketing authorisation in the EU with discussion on the impact of Brexit and the proposed EU legislation changes

  • The EMA
  • The EU centralised procedure

Other EU centralised procedures

  • Referral and arbitration

DAY 2

Other procedures for obtaining a marketing authorisation in the EU

  • Coordination group
  • Decentralised procedure
  • Mutual recognition procedure
  • National procedures

Managing product labelling

Case Study Two

Abridged applications and Generics

  • Types and Requirements

Product Life Cycle; Post approval

Patents and SPCs

Parallel trade

  • How the process works
  • Impact of Brexit

Post-authorisation obligations; pharmacovigilance, variations and renewals

Pharmacovigilance including discussion on the impact of Brexit

Licence variations

  • Type I and Type II variations and timelines
  • Procedures and timelines

Extensions

Case Study Three

Renewals

Sunset clause

Phase IV Trials

Classification change

Generic development

Strategic factors

Criteria for successful products

Speakers

  • Norah Lightowler
  • Ms Norah Lightowler,
    Lightowler Associates


    Norah Lightowler is a partner in Lightowler Associates, an independent consultancy offering regulatory advice and support to pharmaceutical companies in or proposing to enter the European market for human pharmaceuticals. They are in their twentieth year of successful business. Norah has wide experience in the pharmaceutical and related neutraceutical, herbal and devices industries as a pharmaceutical assessor with the UK regulatory authority and as associate director of European regulatory affairs with an international pharmaceutical company. She is experienced in organising and presenting courses on European regulatory control systems, including requirements, procedures and strategy.

Who Should Attend

The course is designed primarily for regulatory affairs personnel, however it will also be of value to those who interact with the regulatory affairs function and would benefit from an understanding of action timelines and information requirements. It will be particularly relevant to all those working in:

  • Regulatory affairs
  • Project management
  • Business planning
  • Commercial management
  • Manufacturing and QA
  • Labelling and artwork
  • Medical information
  • Clinical
  • Pharmacovigilance